Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0028-1095806 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ErbB4 precludes the occurrence of PTSD-like fear responses by supporting the bimodal activity of the central amygdala.
Exp Mol Med
December 2024
Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Nam-gu, Pohang, Gyeongbuk, 37673, Republic of Korea.
Article Synopsis
- PTSD often develops after traumatic events and creates problematic fear responses.
- Research using ErbB4 knockout mice revealed that loss of ErbB4 in specific neurons led to increased fear behaviors similar to PTSD.
- The findings suggest that ErbB4 plays a crucial role in distinguishing between real threats and non-threatening stimuli, particularly in mammalian brain regions associated with fear processing.
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM).
J Endocrinol Invest
January 2025
Nuclear Medicine Department, Foundation IRCCS, Istituto Nazionale Tumori, Milan, Italy.
Article Synopsis
- This paper presents guidelines from major Italian medical associations on the use of radioligand therapy (RLT) for treating neuroendocrine neoplasms (NENs).
- It addresses 10 key questions regarding RLT’s effectiveness in treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs) based on literature review and expert opinions.
- The focus is on well-differentiated GEP-NETs that express somatostatin receptors, identifying which patients are appropriate candidates for RLT according to established international protocols.
Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis.
Pituitary
October 2024
Department of Endocrinology, Normal Regional Hospital, Norman, OK, 73071, USA.
Article Synopsis
- Acromegaly is a rare hormone disorder with significant health issues, and many patients do not respond well to current treatments, prompting this review of the drug pasireotide.
- The study analyzed data from nine studies involving 590 patients, finding that pasireotide achieved biochemical control rates of about 26.5% after one year, alongside improvements in IGF-1 and GH levels.
- However, it also reported common side effects like gastrointestinal issues and hyperglycemia, with a notable increase in new-onset diabetes mellitus at a rate of 23.36% among patients treated with pasireotide.
Phenotypic presentation of c.758delC (p.Ser253Cys 28) pathogenic variant: a case report.
Oxf Med Case Reports
September 2024
Division of Anatomic Pathology and Histology, Catholic University of Sacred Heart, Largo Agostino Gemelli, 8, 00168, Rome, Italy.
Article Synopsis
- - A 32-year-old man with MEN1 syndrome presented with multiple health issues, including hyperparathyroidism, but no prolactin or growth hormone-secreting tumors were found.
- - After a subtotal parathyroidectomy, he was diagnosed with non-functioning pituitary adenoma, pancreatic lesions, and Cushing syndrome linked to an adrenal adenoma.
- - Genetic testing confirmed MEN1 syndrome, revealing a new pathogenic mutation (c.758delC) in the MEN1 gene.
Preclinical evaluation of [Ac]Ac-crown-TATE - An alpha-emitting radiopharmaceutical for neuroendocrine tumors.
Nucl Med Biol
December 2024
Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada; Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada. Electronic address:
Background: Targeted alpha therapy (TAT) of somatostatin receptor-2 (SSTR2) positive neuroendocrine tumors (NETs) involving Ac-225 ([Ac]Ac-DOTA-TATE) has previously demonstrated improved therapeutic efficacy over conventional beta particle-emitting peptide receptor radionuclide therapy agents. DOTA-TATE requires harsh radiolabeling conditions for chelation of [Ac]Ac, which can limit the achievable molar activities and thus therapeutic efficacy of such TAT treatments. Macropa-TATE was recently highlighted as a potential alternative to DOTA-TATE, owing to the mild radiolabeling conditions and high affinity toward [Ac]Ac; however, elevated liver and kidney uptake were noted as a major limitation and a suitable imaging radionuclide is yet to be reported, which will be required for patient dosimetry studies and assessment of therapeutic benefit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!